<version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Quality Measures Clearinghouse (NQMC).</xmlsource>
  <section secid="560" ordby="10" name="General">
    <field fieldid="11" ordby="20" id="561" name="Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Infection control after hematopoietic cell transplantation (HCT): percentage of patients who were expected to be neutropenic for 7 or more days during HCT and were prescribed antibacterial prophylaxis with a fluoroquinolone.</div>"/>
    </field>
    <field fieldid="1" ordby="30" id="562" name="Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Proposed infection control after HCT measure set: questionnaire, patient selection, measures with specifications, glossary. Arlington Heights (IL): American Society for Blood and Marrow Transplantation; 20 p. </td></tr></table>"/>
    </field>
  </section>
  <section secid="563" ordby="40" name="Measure Domain">
    <field fieldid="3025" ordby="50" id="564" name="Primary Measure Domain" type="picklist-one">
      <fieldvalue value="Clinical Quality Measures: Process"/>
    </field>
    <field fieldid="3026" ordby="60" id="565" name="Secondary Measure Domain" type="picklist-one">
      <fieldvalue value="Does not apply to this measure"/>
    </field>
  </section>
  <section secid="566" ordby="70" name="Brief Abstract">
    <field fieldid="34" ordby="80" id="567" name="Description" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This measure is used to assess the percentage of patients greater than or equal to 18 years of age who were expected to be neutropenic for 7 or more days during hematopoietic cell transplantation (HCT) and were prescribed antibacterial prophylaxis with a fluoroquinolone.</p></div>"/>
    </field>
    <field fieldid="21" ordby="90" id="568" name="Rationale" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>In the past decade, modifications in hematopoietic cell transplantation (HCT) management and supportive care have resulted in changes in recommendations for the prevention of infection in HCT patients. These changes are fueled by new antimicrobial agents, increased knowledge of immune reconstitution, and expanded conditioning regimens and patient populations eligible for HCT. Despite these advances, infection is reported as the primary cause of death in 8% of autologous HCT patients and 17% to 20% of allogeneic HCT recipients. </p>
<p><em>Support (verbatim) from guidelines</em>: Antibacterial prophylaxis with a fluoroquinolone (i.e., levofloxacin) to prevent bacterial infections should be strongly considered for adult HCT patients with anticipated neutropenic periods of 7 days or more. Antibacterial prophylaxis is generally started at the time of stem cell infusion and continued until recovery from neutropenia or initiation of empirical antibacterial therapy for fever during neutropenia. The prophylaxis should not be continued after recovery from neutropenia. Local epidemiological data should be carefully considered before applying fluoroquinolone prophylaxis, and once it is applied, the emergence of resistance in bacterial pathogens should be monitored closely because of increasing quinolone resistance worldwide among Gram-negative bacteria (e.g., <em>Escherichia coli</em>, <em>Klebsiella pneumoniae</em>, and <em>Pseudomonas aeruginosa</em>) and staphylococci; plasmid-mediated quinolone resistance in Enterobacteriaceae that is closely related to the beta lactamases that inactivate third-generation cephalosporins; and quinolone-related development of a hypervirulent strain of <em>Clostridium difficile</em>. </p>
<p><em>Note on pediatrics</em>: Because of lack of data, there are currently no antimicrobial prophylactic regimens that can be recommended for children. Some experts use levofloxacin for pediatric antibacterial prophylaxis. </p>
<p><em>Statement (verbatim) from guidelines on gap</em>: Significant changes in the field of HCT since the publication of the original guidelines necessitated this update. These changes include new antimicrobial agents, broader use of reduced-intensity conditioning (RIC), the increasing age of HCT recipients, and more frequent use of alternative donor stem cell sources such as haploidentical donors and umbilical cord blood. Furthermore, as with any field of medicine, published studies continue to add to the evidence regarding supportive medical care. Despite&amp;mdash;or perhaps because of&amp;mdash;these changes, infections still occur with increased frequency or severity among HCT recipients as a patient population.</p>
<p><em>Statement from the American Society for Blood and Marrow Transplantation (ASBMT) Task Force on gap</em>: Fluoroquinolone for bacterial infection prophylaxis is new to the 2009 guidelines from the prior 2000 guidelines. For this reason, we believe there is a significant gap in adoption of this therapy. </p></div>"/>
    </field>
    <field fieldid="3500" ordby="100" id="569" name="Evidence for Rationale" type="citation">
      <fieldvalue value="<table><tr><td>&amp;nbsp;Pasquini MC, Wang Z. &amp;nbsp;Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides. &amp;nbsp;2012. </td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Blahova J, Kralikova K, Krcmery V Sr, Babalova M, Menkyna R, Glosova L, Knotkova H, Liskova A, Molokacova M, Vaculikova A, Bruckmayerova D, Rovny I. Four years of monitoring antibiotic resistance in microorganisms from bacteremic  patients. J Chemother. 2007 Dec;19(6):665-9. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18230547&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Bonadio M, Morelli G, Mori S, Riccioni R, Papineschi F, Petrini M. Fluoroquinolone resistance in hematopoietic stem cell transplant recipients with  infectious complications. Biomed Pharmacother. 2005 Oct;59(9):511-6. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16274955&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Bucaneve G, Castagnola E, Viscoli C, Leibovici L, Menichetti F. Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. Eur J Cancer. 2007;(Suppl 5):5-12.</td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del Favero A, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005 Sep 8;353(10):977-87. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16148283&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, Mengoli C. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol. 2003 Nov 15;21(22):4127-37. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14615441&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis. 1996 Oct;23(4):795-805. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8909847&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol. 1998 Mar;16(3):1179-87. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9508206&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005 Jun 21;142(12 Pt 1):979-95. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15968013&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Kirby JT, Fritsche TR, Jones RN. Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients. Diagn Microbiol Infect Dis. 2006 Sep;56(1):75-82. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16876375&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, Rene P, Monczak Y, Dascal A. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005 Dec 8;353(23):2442-9. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16322602&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis. 2005 Aug 15;41(4):435-40. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16028149&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Oktem IM, Gulay Z, Bicmen M, Gur D, HITIT Project Study Group. qnrA prevalence in extended-spectrum beta-lactamase-positive Enterobacteriaceae isolates from Turkey. Jpn J Infect Dis. 2008 Jan;61(1):13-7. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18219128&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Poirel L, Cattoir V, Nordmann P. Is plasmid-mediated quinolone resistance a clinically significant problem. Clin Microbiol Infect. 2008 Apr;14(4):295-7. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18190576&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Proposed infection control after HCT measure set: questionnaire, patient selection, measures with specifications, glossary. Arlington Heights (IL): American Society for Blood and Marrow Transplantation; 20 p. </td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006 Oct;6(10):629-40. [77 references] <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17008172&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>The European Antimicrobial Resistance Surveillance System (EARSS). Annual report 2006. 2008. </td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ, Center for International Blood and Marrow Research, National Marrow Donor program, European Blood and Marrow Transplant Group, American Society of Blood and Marrow Transplantation, Canadian Blood and Marrow Transplant Group, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, Association of Medical Microbiology and Infectious Disease Canada, Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19747629&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>van de Wetering MD, de Witte MA, Kremer LC, Offringa M, Scholten RJ, Caron HN. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer. 2005 Jul;41(10):1372-82. [44 references] <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15913983&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="3022" ordby="110" id="570" name="Primary Health Components" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Hematopoietic cell transplantation (HCT); neutropenia; antibacterial prophylaxis; fluoroquinolone</p></div>"/>
    </field>
    <field fieldid="23" ordby="120" id="571" name="Denominator Description" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The number of patients in your selection having hematopoietic cell transplantation (HCT) AND expected to be neutropenic for 7 or more days (see the related &quot;Denominator Inclusions/Exclusions&quot; field)</p></div>"/>
    </field>
    <field fieldid="24" ordby="130" id="572" name="Numerator Description" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The number of patients in your selection having hematopoietic cell transplantation (HCT) AND expected to be neutropenic for 7 or more days AND were prescribed fluoroquinolone (see the related &quot;Numerator Inclusions/Exclusions&quot; field)</p></div>"/>
    </field>
  </section>
  <section secid="573" ordby="140" name="Evidence Supporting the Measure">
    <field fieldid="3027" ordby="150" id="574" name="Type of Evidence Supporting the Criterion of Quality for the Measure" type="picklist-choice">
      <fieldvalue value="A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence"/>
      <fieldvalue value="A formal consensus procedure, involving experts in relevant clinical, methodological,  public health and organizational sciences"/>
      <fieldvalue value="A systematic review of the clinical research literature (e.g., Cochrane Review)"/>
      <fieldvalue value="One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal"/>
    </field>
    <field fieldid="3501" ordby="160" id="575" name="Additional Information Supporting Need for the Measure" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="3072" ordby="180" id="577" name="Extent of Measure Testing" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The Infection Control (IC) measure set was developed by the American Society for Blood and Marrow Transplantation (ASBMT) using a rigorous methodology (adapted from the American Medical Association's Physician Consortium for Performance Improvement [AMA-PCPI] and including field testing) and adapted for use in Practice Improvement Modules (PIMs) by the American Board of Internal Medicine (ABIM).</p></div>"/>
    </field>
    <field fieldid="3007" ordby="190" id="578" name="Evidence for Extent of Measure Testing" type="citation">
      <fieldvalue value="<table><tr><td>Joseph TL. (Executive Director, American Society for Blood and Marrow Transplantation). Personal communication. 2013 Jan 21. &amp;nbsp;1 p. </td></tr></table>"/>
    </field>
  </section>
  <section secid="580" ordby="210" name="State of Use of the Measure">
    <field fieldid="3029" ordby="220" id="581" name="State of Use" type="picklist-one">
      <fieldvalue value="Current routine use"/>
    </field>
    <field fieldid="3030" ordby="230" id="582" name="Current Use" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
  </section>
  <section secid="583" ordby="240" name="Application of the Measure in its Current Use">
    <field fieldid="3031" ordby="250" id="584" name="Measurement Setting" type="picklist-choice">
      <fieldvalue value="Ambulatory/Office-based Care"/>
      <fieldvalue value="Hospital Inpatient"/>
      <fieldvalue value="Hospital Outpatient"/>
      <fieldvalue value="Intensive Care Units"/>
    </field>
    <field fieldid="3032" ordby="260" id="585" name="Professionals Involved in Delivery of Health Services" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="3033" ordby="270" id="586" name="Least Aggregated Level of Services Delivery Addressed" type="picklist-one">
      <fieldvalue value="Clinical Practice or Public Health Sites"/>
    </field>
    <field fieldid="3505" ordby="280" id="587" name="Statement of Acceptable Minimum Sample Size" type="picklist-one">
      <fieldvalue value="Specified"/>
    </field>
    <field fieldid="41" ordby="290" id="588" name="Target Population Age" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Age greater than or equal to&amp;nbsp;18 years </p></div>"/>
    </field>
    <field fieldid="42" ordby="300" id="589" name="Target Population Gender" type="picklist-one">
      <fieldvalue value="Either male or female"/>
    </field>
  </section>
  <section secid="660" ordby="310" name="National Strategy for Quality Improvement in Health Care">
    <field fieldid="3522" ordby="320" id="661" name="National Quality Strategy Aim" type="text">
      <fieldvalue value="<ul><li>Better Care</li></ul>"/>
    </field>
    <field fieldid="3525" ordby="330" id="662" name="National Quality Strategy Priority" type="text">
      <fieldvalue value="<ul><li>Making Care Safer</li><li>Prevention and Treatment of Leading Causes of Mortality</li></ul>"/>
    </field>
  </section>
  <section secid="590" ordby="340" name="Institute of Medicine (IOM) National Health Care Quality Report Categories">
    <field fieldid="3163" ordby="350" id="591" name="IOM Care Need" type="picklist-choice">
      <fieldvalue value="Living with Illness"/>
    </field>
    <field fieldid="3164" ordby="360" id="592" name="IOM Domain" type="picklist-choice">
      <fieldvalue value="Effectiveness"/>
      <fieldvalue value="Safety"/>
    </field>
  </section>
  <section secid="593" ordby="370" name="Data Collection for the Measure">
    <field fieldid="3506" ordby="380" id="594" name="Case Finding Period" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>12 months</p></div>"/>
    </field>
    <field fieldid="3054" ordby="390" id="595" name="Denominator Sampling Frame" type="picklist-one">
      <fieldvalue value="Patients associated with provider"/>
    </field>
    <field fieldid="3057" ordby="400" id="598" name="Denominator (Index) Event or Characteristic" type="picklist-choice">
      <fieldvalue value="Clinical Condition"/>
      <fieldvalue value="Encounter"/>
      <fieldvalue value="Therapeutic Intervention"/>
    </field>
    <field fieldid="3058" ordby="410" id="599" name="Denominator Time Window" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="55" ordby="420" id="596" name="Denominator Inclusions/Exclusions" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Inclusions </strong><br />
The number of patients in your selection having hematopoietic cell transplantation (HCT) AND expected to be neutropenic for 7 or more days</p>
<p class=&quot;Note&quot;><strong>Note</strong>: Patients can be included in the chart abstraction if: </p>
<ul class=&quot;Note&quot; style=&quot;list-style-type: disc;&quot;>
    <li>They have been seen by the practice within the past 12 months; and </li>
    <li>Management decisions regarding care are made primarily by providers in the practice. </li>
</ul>
<p class=&quot;Note&quot;>Select at least 25 of your patients who have had HCT. Refer to the original measure documentation for administrative codes.</p>
<p><strong>Exclusions</strong> <br />
Patients less than 18 years old </p></div>"/>
    </field>
    <field fieldid="3507" ordby="430" id="597" name="Exclusions/Exceptions" type="picklist-choice-4">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="59" ordby="440" id="600" name="Numerator Inclusions/Exclusions" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Inclusions</strong><br />
The number of patients in your selection having hematopoietic cell transplantation (HCT) AND expected to be neutropenic for 7 or more days AND were prescribed fluoroquinolone </p>
<p class=&quot;Note&quot;><strong>Note</strong>: This requires documentation in the patient's medical record that fluoroquinolone therapy was prescribed as described in the guidelines (see the original measure documentation for details).</p>
<p><strong>Exclusions</strong><br />
None</p></div>"/>
    </field>
    <field fieldid="3061" ordby="450" id="601" name="Numerator Search Strategy" type="picklist-one">
      <fieldvalue value="Fixed time period or point in time"/>
    </field>
    <field fieldid="3062" ordby="460" id="602" name="Data Source" type="picklist-many">
      <fieldvalue value="Administrative clinical data"/>
      <fieldvalue value="Paper medical record"/>
    </field>
    <field fieldid="3065" ordby="470" id="603" name="Type of Health State" type="picklist-one">
      <fieldvalue value="Does not apply to this measure"/>
    </field>
    <field fieldid="3066" ordby="480" id="604" name="Instruments Used and/or Associated with the Measure" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
  </section>
  <section secid="605" ordby="490" name="Computation of the Measure">
    <field fieldid="3508" ordby="500" id="606" name="Measure Specifies Disaggregation" type="picklist-one">
      <fieldvalue value="Does not apply to this measure"/>
    </field>
    <field fieldid="3067" ordby="520" id="608" name="Scoring" type="picklist-many">
      <fieldvalue value="Rate/Proportion"/>
    </field>
    <field fieldid="3068" ordby="530" id="609" name="Interpretation of Score" type="picklist-one">
      <fieldvalue value="Desired value is a higher score"/>
    </field>
    <field fieldid="3090" ordby="540" id="610" name="Allowance for Patient or Population Factors" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="3070" ordby="560" id="612" name="Standard of Comparison" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
  </section>
  <section secid="615" ordby="590" name="Identifying Information">
    <field fieldid="73" ordby="600" id="616" name="Original Title" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Patients who were expected to be neutropenic for 7 or more days during HCT and were prescribed antibacterial prophylaxis with a fluoroquinolone.</p></div>"/>
    </field>
    <field fieldid="74" ordby="610" id="617" name="Measure Collection Name" type="text">
      <fieldvalue value="Infection Control after Hematopoietic Cell Transplantation Measure Set"/>
    </field>
    <field fieldid="16" ordby="650" id="621" name="Submitter" type="orglist">
      <fieldvalue value="American Society for Blood and Marrow Transplantation - Professional Association"/>
    </field>
    <field fieldid="17" ordby="660" id="622" name="Developer" type="orglist-p">
      <fieldvalue value="American Society for Blood and Marrow Transplantation - Professional Association"/>
    </field>
    <field fieldid="79" ordby="670" id="623" name="Funding Source(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>American Society for Blood and Marrow Transplantation</p></div>"/>
    </field>
    <field fieldid="80" ordby="680" id="624" name="Composition of the Group that Developed the Measure" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The American Society for Blood and Marrow Transplantation (ASBMT) Education Practice Improvement Modules Task Force:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Linda Burns, MD (<em>chair</em>) </li>
    <li>Stephan A Grupp, MD, PhD </li>
    <li>Mark B Juckett, MD </li>
    <li>Vivek Roy, MD </li>
    <li>Edward Agura, MD </li>
    <li>Miguel-Angel Perales, MD </li>
    <li>Thomas Joseph, MPS, CAE, ASBMT Executive Director </li>
    <li>Sue Frechette, BSN, MBA Consultant </li>
</ul></div>"/>
    </field>
    <field fieldid="81" ordby="690" id="625" name="Financial Disclosures/Other Potential Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Conflicts, if any, are disclosed in accordance with the American Society for Blood and Marrow Transplantation (ASBMT) conflict of interest policy.</p></div>"/>
    </field>
    <field fieldid="19" ordby="730" id="629" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This measure was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="3086" ordby="740" id="630" name="Date of Most Current Version in NQMC" type="date">
      <fieldvalue value="2012 Apr"/>
    </field>
    <field fieldid="3511" ordby="750" id="631" name="Measure Maintenance" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="3512" ordby="760" id="632" name="Date of Next Anticipated Revision" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="20" ordby="770" id="633" name="Measure Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the measure.</p>
<p>The measure developer reaffirmed the currency of this measure in February 2017. </p></div>"/>
    </field>
    <field fieldid="14" ordby="780" id="634" name="Measure Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Source not available electronically.</p>
<p>For more information, contact the American Society for Blood and Marrow Transplantation (ASBMT) at 85 W. Algonquin Road, Suite 550, Arlington Heights, IL 60005; Phone: 847-427-0224; Fax: 847-427-9656; Web site: <a href=&quot;http://www.asbmt.org&quot; title=&quot;ASBMT Web site&quot;>www.asbmt.org</a>; E-mail: <a href=&quot;mailto:mail@asbmt.org&quot;>mail@asbmt.org</a>.</p></div>"/>
    </field>
    <field fieldid="87" ordby="800" id="636" name="NQMC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NQMC summary was completed by ECRI Institute on September 24, 2013. The information was verified by the measure developer on October 25, 2013.</p>
<p>The information was reaffirmed by the measure developer on February 8, 2017. </p></div>"/>
    </field>
    <field fieldid="88" ordby="810" id="637" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.</p></div>"/>
    </field>
  </section>
  <section secid="641" ordby="850" name="Production">
    <field fieldid="1" ordby="1366" id="562" name="Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Proposed infection control after HCT measure set: questionnaire, patient selection, measures with specifications, glossary. Arlington Heights (IL): American Society for Blood and Marrow Transplantation; 20 p. </td></tr></table>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NQMC Disclaimer" type="text">
      <fieldvalue value="<p>The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.</p> 
<p>All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.</p> 
<p>Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NQMC Inclusion Criteria</a>.</p> 
<p>NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding measure content are directed to contact the measure developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 10:37:33 Jun 30, 2017 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 23:30:46 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 496.784 (3)
  esindex: 0.01
  captures_list: 524.646
  CDXLines.iter: 9.509 (3)
  PetaboxLoader3.datanode: 788.424 (4)
  exclusion.robots: 0.108
  exclusion.robots.policy: 0.101
  RedisCDXSource: 15.887
  PetaboxLoader3.resolve: 731.937
  load_resource: 1027.581
-->